
中东和非洲循环肿瘤细胞 (CTC) 诊断市场预测至 2028 年 - COVID-19 影响和区域技术分析(CTC 检测和富集方法、CTC 直接检测方法和 CTC 分析)、应用(临床/液体活检和研究)和最终用户(医院和诊所、研究和学术机构以及诊断中心)
No. of Pages: 117 | Report Code: TIPRE00028648 | Category: Life Sciences
No. of Pages: 117 | Report Code: TIPRE00028648 | Category: Life Sciences
循环肿瘤细胞脱落到来自原发肿瘤的脉管系统,并在血液循环的帮助下输送到全身。这些循环肿瘤细胞是转移性疾病的征兆,它们的检测有助于在疾病的早期阶段诊断并为患者设计适当的治疗方案。近年来,用于诊断的循环肿瘤细胞的分离方法取得了重大进展。免疫亲和力、物理特性和直接分析是用于分离循环肿瘤细胞的几种方法。免疫亲和是使用磁珠、微流体、纳米结构基质、微管和白细胞去除来捕获目标细胞上存在的抗体和靶抗原的亲和反应。微管方法使用仿生方法来刺激选择素介导的细胞粘附过程以捕获 CTC。即使在 4.8 ml/h 的高流速下,选择素包被的微管也会诱导细胞附着和滚动,从而促进 CTC 与抗 EpCAM(即上皮细胞粘附分子)和抗 PSMA 抗体结合。该设备的捕获效率为 50%,平均纯度为 66%,在检查的 14 份患者血液样本中,有 14 份检测到了循环肿瘤细胞,而 CellSearch 系统在 14 份血液样本中检测到了 9 份。物理特性也用于从外周血细胞中分离循环肿瘤细胞。用于分离 CTC 的一些常见物理特性包括密度梯度离心、微滤、微流体和介电泳。因此,循环肿瘤细胞的各种分离技术的持续发展和进步预计将在未来几年获得关注。
由于新冠病毒大流行,医疗保健提供者不得不减少诊断服务和筛查项目的数量,以调整其对这种疾病的管理力度。结果,癌症患者变得更容易受到严重感染,并面临癌症或标准医疗护理中断等问题。 COVID-19 患者住院率上升带来的压力加大,导致许多医院和科室(包括肿瘤诊所)重新调整,以治疗 COVID-19 患者。这些因素损害了中东和非洲循环肿瘤细胞(CTC)诊断市场的进展。
随着新功能和技术的出现,供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动循环肿瘤细胞(CTC)诊断市场的发展。中东和中东地区非洲循环肿瘤细胞 (CTC) 诊断市场预计在预测期内将以良好的复合年增长率增长。
中东和中东非洲循环肿瘤细胞 (CTC) 诊断市场细分
按技术
span>
Strategic insights for Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 75.3 Million |
Market Size by 2028 | US$ 131.3 Million |
Global CAGR (2021 - 2028) | 8.3% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 技术
|
Regions and Countries Covered | 中东和非洲
|
Market leaders and key company profiles |
The regional scope of Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market is valued at US$ 75.3 Million in 2021, it is projected to reach US$ 131.3 Million by 2028.
As per our report Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market, the market size is valued at US$ 75.3 Million in 2021, projecting it to reach US$ 131.3 Million by 2028. This translates to a CAGR of approximately 8.3% during the forecast period.
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report:
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.